Vasoactive intestinal peptide-VIPR2 signaling regulates tumor cell migration.
GPCR
VIPR2
breast cancer
cell migration
cytoskeleton
phosphatidylinositol signaling
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2022
accepted:
24
08
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Phosphoinositide metabolism is critically involved in human cancer cell migration and metastatic growth. The formation of lamellipodia at the leading edge of migrating cells is regulated by metabolism of the inositol phospholipid PI(4,5)P
Identifiants
pubmed: 36237322
doi: 10.3389/fonc.2022.852358
pmc: PMC9550923
doi:
Types de publication
Journal Article
Langues
eng
Pagination
852358Informations de copyright
Copyright © 2022 Asano, Yamasaka, Ozasa, Sakamoto, Hayata-Takano, Nakazawa, Hashimoto, Waschek and Ago.
Déclaration de conflit d'intérêts
Kotaro Sakamoto is a full-time employee of Ichimaru Pharcos Co. Ltd. The authors declare that this study received funding from Ichimaru Pharcos Co. Ltd. The funder had the following involvement in the study: interpretation of data. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
F1000Prime Rep. 2015 Feb 03;7:13
pubmed: 25750731
Cancer Res. 2000 Jun 1;60(11):3105-12
pubmed: 10850463
Endocrinology. 2001 Mar;142(3):1209-17
pubmed: 11181537
Biol Open. 2014 May 08;3(6):463-74
pubmed: 24812354
Science. 1994 Mar 18;263(5153):1609-12
pubmed: 8128248
Nat Immunol. 2001 Feb;2(2):129-34
pubmed: 11175805
Nat Cell Biol. 2004 May;6(5):420-6
pubmed: 15107862
Front Neurosci. 2020 Jun 04;14:521
pubmed: 32581681
Cell. 2000 Sep 1;102(5):635-46
pubmed: 11007482
Science. 2005 Feb 18;307(5712):1098-101
pubmed: 15718470
Ann N Y Acad Sci. 1996 Dec 26;805:579-84
pubmed: 8993443
Science. 2019 Nov 8;366(6466):685-686
pubmed: 31699922
Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):38-47
pubmed: 26702849
Br J Pharmacol. 2012 May;166(1):4-17
pubmed: 22289055
Br J Pharmacol. 2013 Jun;169(3):512-23
pubmed: 23517078
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
J Biol Chem. 1996 Jan 19;271(3):1660-8
pubmed: 8576167
Clin Cancer Res. 2006 Apr 15;12(8):2449-54
pubmed: 16638851
Int J Oncol. 2005 Jun;26(6):1629-35
pubmed: 15870879
J Pharmacol Exp Ther. 2012 Jun;341(3):873-81
pubmed: 22389426
Nat Rev Cancer. 2009 Aug;9(8):550-62
pubmed: 19629070
J Biochem. 2003 Sep;134(3):309-13
pubmed: 14561714
Cell Signal. 2018 Oct;50:37-47
pubmed: 29935235
Methods Mol Biol. 2011;769:1-24
pubmed: 21748665
Mol Cell Biol. 2012 Aug;32(16):3242-52
pubmed: 22688512
Mol Cell. 2001 May;7(5):937-47
pubmed: 11389841
Cancer Biol Ther. 2004 Aug;3(8):772-5
pubmed: 15254419
Endocr Connect. 2015 Mar;4(1):18-26
pubmed: 25504760
Int J Oncol. 2011 Oct;39(4):1019-24
pubmed: 21769421
Peptides. 2021 Mar;137:170480
pubmed: 33385499
Pharmacol Rev. 2009 Sep;61(3):283-357
pubmed: 19805477
Nat Rev Mol Cell Biol. 2005 Feb;6(2):167-80
pubmed: 15688002
Mod Pathol. 2007 Mar;20(3):339-43
pubmed: 17277766
Cell. 1994 Apr 8;77(1):83-93
pubmed: 8156600
Cell. 2011 Jun 24;145(7):1012-22
pubmed: 21703446
Med Oncol. 2019 Sep 27;36(11):91
pubmed: 31560089
Front Pharmacol. 2021 Nov 04;12:751587
pubmed: 34819858
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Anal Bioanal Chem. 2011 Oct;401(6):1881-8
pubmed: 21789487
Curr Opin Cell Biol. 2017 Apr;45:62-71
pubmed: 28343126
Sci Rep. 2017 Jul 14;7(1):5408
pubmed: 28710365
J Mol Neurosci. 2014 Nov;54(3):388-94
pubmed: 25091859
Peptides. 2003 Jan;24(1):163-77
pubmed: 12576099
Sci Rep. 2019 Sep 4;9(1):12729
pubmed: 31484968
Cell Tissue Res. 2000 May;300(2):219-30
pubmed: 10867818